Apoptosis
Apoptosis inhibitors are compounds that prevent or delay the process of programmed cell death, known as apoptosis. These inhibitors are vital in studying cell survival mechanisms and are used to investigate diseases where apoptosis is dysregulated, such as cancer, neurodegenerative disorders, and autoimmune diseases. By modulating apoptosis, these inhibitors can help in the development of therapies aimed at controlling cell death. At CymitQuimica, we provide a comprehensive selection of high-quality apoptosis inhibitors to support your research in cell biology, oncology, and related fields.
Subcategories of "Apoptosis"
- ASK(9 products)
- BCL(1 products)
- Caspase(154 products)
- FOXO1(2 products)
- IAP(67 products)
- Mdm2(12 products)
- PD-1/PD-L1(126 products)
- PDK(9 products)
- PERK(23 products)
- Serine/threonin kinase(17 products)
- Survivin(14 products)
- TNF(91 products)
- c-RET(61 products)
- p53(63 products)
Show 6 more subcategories
Found 6170 products of "Apoptosis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Izuralimab
CAS:Izuralimab is a bispecific IgG1 antibody that targets both the inducible T-cell costimulator (ICOS/CD278) and PD-1 [1].Color and Shape:LiquidPamrevlumab
CAS:FG-3019 (Pamrevlumab), a human antibody, targets CTGF, potentially treating idiopathic pulmonary fibrosis.Purity:100% (SEC-HPLC) - >95.0% (SDS-PAGE)Color and Shape:LiquidMolecular weight:150 kDaEfaprinermin alfa
CAS:Efaprimermin alfa (OMP-336B11) is a human monoclonal antibody that targets TNFRSF18, and functions as a GITR ligand-Fc fusion protein [1].Color and Shape:LiquidLatikafusp
CAS:Latikafusp (AMG 256) is a fusion protein that is a PD-1 blocker and IL-21R agonist with antitumor activity.Purity:97.1% (SDS-PAGE); 97.4% (SEC-HPLC) - 97.1% (SDS-PAGE); 97.4% (SEC-HPLC)Color and Shape:LiquidMolecular weight:159.55 kDaLenercept
CAS:Lenercept (Ro 45-2081) is a recombinant fusion protein combining the soluble TNF-receptor (p55) with the Fc portion of human IgG1 [1].Color and Shape:LiquidManelimab
CAS:Manelimab is a monoclonal antibody that inhibits programmed death-ligand 1 ( PD-L1 ) [1] .Color and Shape:LiquidAnti-Mouse CD44 Antibody (IM7)
Anti-Mouse CD44 Antibody (IM7) is a monoclonal antibody targeting CD44 in mice.Purity:99%Color and Shape:Odour LiquidMolecular weight:150 kDaThalidomide-NH-C6-NH-Boc
CAS:Thalidomide-based E3 ligase ligand for PROTAC degrader MI-389 synthesis, linked to cereblon and Boc.Formula:C24H32N4O6Color and Shape:SolidMolecular weight:472.542Balstilimab
CAS:Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1 [1] .Color and Shape:LiquidAtacicept
CAS:Atacicept (TACI-Ig) is a homodimeric fusion protein that inhibits B cell stimulation.Purity:97.9% (SDS-PAGE); 98.7% (SEC-HPLC) - 97.9% (SDS-PAGE); 98.7% (SEC-HPLC)Color and Shape:LiquidMolecular weight:35.36 kDaNFh-NMe-2
NFh-NMe-2 is a photosensitizer that interacts with nitroreductase (nitroreductase) to generate singlet oxygen in tumor cells, exhibiting cytotoxicity in cancer cells and inducing apoptosis (apoptosis). In mouse models, NFh-NMe-2 demonstrates antitumor activity.
Formula:C32H33IN2OColor and Shape:SolidMolecular weight:588.522Vinepidine sulfate
CAS:Vinepidine (LY-119863) sulfate, a derivative of vincristine, exhibits antitumor activity .Formula:C46H58N4O13SColor and Shape:SolidMolecular weight:907.04FLT3-IN-28
FLT3-IN-28 (Compound 12y) is an orally active FLT3 inhibitor with antitumor properties. It selectively targets cancer cells with FLT3 internal tandem duplication (ITD) mutations, demonstrating IC50 values of 85, 290, 130, 65, and 220 nM against BaF3-FLT3-ITD, BaF3-TEL-VEGFR2, MV4-11, MOLM-13, and MOLM-14 cell lines, respectively. These lines include acute myeloid leukemia (AML) cells harboring FLT3-ITD mutations such as MV4-11 and MOLM-13/14. The compound also reduces phosphorylation levels of FLT3 and STAT5 in MOLM-13 cells, leading to cell cycle arrest and apoptosis. With an oral bioavailability of 19.2% in SD rats, FLT3-IN-28 extends survival in a dose-dependent manner in MOLM-13 xenografted NSG mouse models. It holds promise for research in FLT3-ITD-related cancer studies.Formula:C23H19FN8O4Color and Shape:SolidMolecular weight:490.447MKC-1
CAS:MKC-1 (Ro-31-7453) is an oral bisindolylmaleimide inhibitor that disrupts tubulin polymerization, potentially halting cancer cell division.Formula:C22H16N4O4Purity:99.63% - 99.85%Color and Shape:SolidMolecular weight:400.39Ref: TM-T9831
1mg54.00€5mg118.00€10mg168.00€25mg293.00€50mg423.00€100mg588.00€500mgTo inquire1mL*10mM (DMSO)127.00€AB-3PRGD2
CAS:AB-3PRGD2 is a radiolabeled agent that targets integrin αvβ3. It enhances tumor uptake and prolongs retention time in tumors, significantly improving the inhibition of tumor growth. AB-3PRGD2 also remodels the tumor immune microenvironment by upregulating PD-L1 expression and increasing tumor-infiltrating CD8+ T cells.
Formula:C137H215IN30O45SColor and Shape:SolidMolecular weight:3161.32GSPT1 degrader-1
GSPT1 Degrader-1 (Compound 9q) effectively facilitates the degradation of G1 to S phase transition 1 (GSPT1) through the ubiquitin-proteasome system and inducesFormula:C28H33ClN4O5Purity:98%Color and Shape:SolidMolecular weight:541.04Thalidomide-O-C8-COOH
CAS:Thalidomide-O-C8-COOH, also known as Cereblon ligand 3, is a Thalidomide-derived compound that serves as a Cereblon (CRBN) ligand for the targeted recruitmentFormula:C22H26N2O7Color and Shape:SolidMolecular weight:430.45Z-WEHD-FMK
CAS:Z-WEHD-FMK is a cell-permeable and irreversible inhibitor of caspase-1/5. It also shows a robust inhibitory effect on cathepsin B activity (IC50: 6 μM).Formula:C37H42FN7O10Purity:98%Color and Shape:SolidMolecular weight:763.78IRAK4-IN-27
IRAK4-IN-27 (Compound 22) is a potent and selective IRAK4 inhibitor, demonstrating an IC50 of 8.7 nM.Formula:C23H22N6O3Purity:98%Color and Shape:SolidMolecular weight:430.46TAT-BH4 (Bcl-xL) (TFA)
"TAT-BH4 (Bcl-xL) TFA, primarily localized at the mitochondria, inhibits apoptotic cell death.Formula:C159H268N58O45·xC2HF3O2Purity:98%Color and Shape:SolidMolecular weight:3712.19 (free acid)FF2049
FF2049 is a selective HDAC PROTAC degrader with a DC50 of 257 nM for HDAC1. It facilitates the ubiquitination and degradation of HDAC and promotes apoptosis (Apoptosis). FF2049 is applicable in research involving hematological and solid tumors.Formula:C31H38ClN7O7Color and Shape:SolidMolecular weight:656.129PROTAC LZK-IN-1
CAS:PROTAC LZK-IN-1 (Compound 21A) is a PROTAC molecule that targets the degradation of LZK (leucine zipper kinase, encoded by MAP3K13). At a concentration of 10 μM, PROTAC LZK-IN-1 facilitates the degradation of LZK and inhibits the expression of p53 and c-MYC, leading to reduced viability of global head and neck squamous cell carcinoma (HNSCC) cell lines. This compound is applicable in anticancer research.
Formula:C51H64F2N10O5SColor and Shape:SolidMolecular weight:967.18BRAFV600E/JNK-IN-1
BRAFV600E/JNK-IN-1 (Compound 14c) is an inhibitor of JNK1, JNK2, JNK3, and BRAFV600E, with IC50 values of 0.51 μM, 0.53 μM, 1.02 μM, and 0.009 μM, respectively. It also inhibits the phosphorylation of MEK1/2 and ERK1/2. Additionally, BRAFV600E/JNK-IN-1 suppresses tumor cell proliferation, NO release, and PGE2 production, exhibiting both antitumor and anti-inflammatory activities.Color and Shape:Odour SolidYX-02-030
CAS:YX-02-030M is a PROTACMDM2 degrader. It inhibits the binding of MDM2 to p53 and VHL to HIF1α, with IC50 values of 63 nM and 1.35 μM, respectively. YX-02-030M binds to MDM2 and recruits the VHL E3 ubiquitin ligase to initiate MDM2 degradation, effectively killing p53 mutant or deficient triple-negative breast cancer (TNBC) cells.
Formula:C66H85Cl2N9O10SMolecular weight:1267.41PRMT5-IN-33
PRMT5-IN-33 (compound A8) is a selective inhibitor of PRMT5 that competes with SAM, exhibiting an IC50 of 10.9 nM. It induces apoptosis and inhibits the proliferation of Z-138 and MOLM-13 cells, demonstrating antitumor activity.Formula:C25H24BrN5O3SMolecular weight:553.07832Antiproliferative agent-27
Antiproliferative Agent-27 (Compound 11) is a notable antiproliferative agent that markedly diminishes tumor cell colony formation and induces apoptosis,Formula:C26H40FNO6SPurity:98%Color and Shape:SolidMolecular weight:513.66PROTAC EGFR degrader 9
CAS:PROTACEGFRdegrader 9 (Compound C6) is an orally active, CRBN-based PROTAC EGFR degrader. It has a DC50 of 10.2 nM and a Kd of 240.2 nM against EGFRL858R/T790M/C797S. PROTACEGFRdegrader 9 demonstrates effective degradation activity against various EGFR mutants while not affecting EGFRWT.
Formula:C45H48F3N9O6SMolecular weight:899.98TrxR-IN-7
TrxR-IN-7 (14f) is a potent inhibitor of thioredoxin reductase (TrxR), with an IC50 value of 3.5 µM. It exhibits antiproliferative activity and can induce apoptosis and the production of reactive oxygen species (ROS).Formula:C22H21NO3Color and Shape:SolidMolecular weight:347.407Ferroptosis-IN-1
Ferroptosis-IN-1, a diterpene derived from A.Formula:C22H34O5Purity:98%Color and Shape:SolidMolecular weight:378.5Antimycobacterial agent-5
Antimycobacterial agent-5 (compound 27) is an imidazopyridine amide compound that targets the Mycobacterium electron transport chain (ETC) respiratory CIII2CIV2 supercomplex. It acts on Mycobacterium smegmatis CIII2CIV2 with an IC50 of 441 nM.Formula:C25H34ClN3OMolecular weight:427.23904TAT-BH4 (Bcl-xL)
TAT-BH4 (Bcl-xL), primarily localized at the mitochondria, inhibits apoptotic cell death.Formula:C159H268N58O45Purity:98%Color and Shape:SolidMolecular weight:3712.19Topoisomerase II inhibitor 17
TopoisomeraseII inhibitor 17 (compound 4c) is a thiazolopyrimidine-based inhibitor of Topoisomerase II with an IC50 of 0.23 μM. This compound significantly disrupts the cell cycle and induces apoptosis.Formula:C25H22Cl3N3O5SMolecular weight:581.03458RIP1 kinase inhibitor 9
RIP1 kinase inhibitor 9 (compound SY-1) is a selective inhibitor of RIP kinase. It effectively reduces central inflammatory responses caused by seizures. RIP1 kinase inhibitor 9 also obstructs Z-VAD-FMK-induced necroptosis in HT-29 cells, with an EC50 of 7.04 nM.Formula:C25H21N3O3Molecular weight:411.15829TS-IN-5
TS-IN-5 (Compound 15) is an inhibitor of thymidylate synthase (TS). It induces apoptosis by modulating the proteins Bax, BCL-2, PI3K, and STAT1. TS-IN-5 exhibits antitumor activity against liver cancer, breast cancer, and colon cancer.Formula:C16H17N5OSColor and Shape:SolidMolecular weight:327.404PROTAC PD-L1 degrader-1
PROTACPD-L1 degrader-1 is a CRBN-based PD-L1-PROTAC degrader with significant PD-L1 protein degradation capacity. It demonstrates strong PD-L1 degradation activity in 4T1 cells, with a DC50 of 0.609 μM. This compound is applicable to breast cancer research.ECDD-S16
ECDD-S16 is a potent inhibitor of pyroptosis. It effectively suppresses pyroptosis in Raw264.7 cells activated by surface and endosomal TLR ligands.Formula:C35H31FO12Molecular weight:662.17995Antitumor agent-170
Antitumor agent-170 (Compound C6) inhibits PD-1/PD-L1 interaction and PARP7 with IC50 values of 0.342 μM and 7.05 nM, respectively. It shows high affinity for human PD-L1, with a Ki of 9.31 nM, and can restore T cell function while increasing IFN-γ secretion. In mouse models, Antitumor agent-170 exhibits antitumor effects against melanoma and demonstrates favorable pharmacokinetic properties.Formula:C59H69ClF3N11O9Molecular weight:1167.49204Anticancer agent 178
Anticanceragent 178 (compound C2) is a potent anticancer compound. It effectively inhibits the proliferation and metabolic activity of MDA-MB 231 cells, with IC50 values of 1.1 and 4.2 μM, respectively. Additionally, Anticanceragent 178 induces ferroptosis and necroptosis in cells.Formula:C32H30ClFeN2O6Molecular weight:629.11418HDAC6-IN-28
HDAC6-IN-28 (compound 10C) is a potent inhibitor of HDAC6 with an IC50 of 261 nM. It significantly induces apoptosis in B16-F10 cells and causes S phase arrest. Additionally, HDAC6-IN-28 effectively increases the expression of acetylated-α-tubulin both in vitro and in vivo.
Formula:C23H16FN3O2Molecular weight:385.12265LC-1-40
LC-1-40 is a PROTAC that selectively degrades NUDT1 (DC50=0.97 nM). In mouse models, LC-1-40 selectively inhibits tumor growth induced by MYCN and induces nucleotide damage and apoptosis (cell death) in MYCN-associated tumors. It is applicable for cancer research.Formula:C49H48N8O6Molecular weight:844.36968NCA029
NCA029 is a potent activator of human caseinolytic protease P (HsClpP) with an EC50 of 0.15 μM. It targets HsClpPP and triggers an ATF3-dependent integrated stress response, resulting in the death of colon cancer cells.Formula:C22H20F3N3OMolecular weight:399.15585RIPK2-IN-4
RIPK2-IN-4 is a potent and specific inhibitor of RIPK2 with an IC50 value of 5 nM.Formula:C16H10N6S2Molecular weight:350.04084MALT1-IN-13
MALT1-IN-13 (compound 10m) is an inhibitor of the mucosa-associated lymphoid tissue lymphoma translocation protein (MALT1), forming a covalent and irreversible bond with the MALT1 protease, thereby inhibiting its activity with an IC50 of 1.7 μM. It suppresses the proliferation of ABC-DLBCL and induces apoptosis in ABC-DLBCL HBL1 cells. Additionally, MALT1-IN-13 regulates the mTOR and PI3K-Akt pathways.Formula:C20H15BrClN3O3S2Molecular weight:522.94267Ascochlorin
CAS:Ascochlorin, an isoprenoid antibiotic, inhibits STAT3 to combat tumors, induces apoptosis, and reduces inflammation.Formula:C23H29ClO4Purity:98%Color and Shape:SolidMolecular weight:404.93Ferroptosis-IN-3
Ferroptosis-IN-3 (Compound 25), a ferroptosis inhibitor, demonstrates potent activity by inhibiting RSL3-induced ferroptosis in HT-1080 cells (EC50: 8.6 nM).Purity:98%Color and Shape:Odour SolidCamrelizumab
CAS:Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity and directed against PD-1.Camrelizumab binds PD-1 with a binding affinity of up
Purity:95% - 98.6%Color and Shape:LiquidMolecular weight:143.7 kDaRWJ-56110 dihydrochloride
CAS:RWJ-56110 dihydrochloride is a potent PAR-1 inhibitor (IC50=0.44μM), blocking platelet aggregation, angiogenesis, and induces apoptosis. No PAR-2/3/4 effect.Formula:C41H44Cl3F2N7O3Color and Shape:SolidMolecular weight:827.2Lw13
Lw13 is a PROTAC targeting Hsp90, exhibiting maximal degradation efficacy at a concentration of 0.05 μM in Siha cells. Lw13 induces apoptosis and demonstrates potent antitumor activity both in vitro and in vivo.Formula:C46H55F3N8O8Molecular weight:904.4095Caerin 1.1 TFA
Caerin 1.1 TFA, a host defense peptide derived from the Australian tree frog Litoria's glandular secretions, exhibits anti-proliferative effects on HeLa cellsPurity:98%Color and Shape:Odour SolidAnticancer agent 146
Anticancer Agent 146 (Compound 1.19) acts as a necroptosis inducer and demonstrates anti-tumor efficacy in the MDA-MB-231 mouse xenograft model [1].Formula:C19H16Cl2N2O2Purity:98%Color and Shape:SolidMolecular weight:375.25RIP1-IN-1
RIP1-IN-1 is an orally bioavailable RIP1 inhibitor with a high binding affinity (Kd: 110 nM). This compound exhibits significant activity against necroptosis and effectively suppresses necrosome formation by inhibiting the phosphorylation of RIP1, RIP3, and MLKL pathways. RIP1-IN-1 can inhibit necroptosis and is applicable in research on acute liver injury.Color and Shape:Odour SolidAnticancer agent 136
Anticancer agent 136 (compound 22), a C17-triazole analogue of Geldanamycin (GDM), exhibits an IC50 value of 3.38 μM against human dermal fibroblasts (HDF) andFormula:C40H50N6O8Purity:98%Color and Shape:SolidMolecular weight:742.86Pacmilimab
CAS:Pacmilimab (CX-072) is a Probody immune checkpoint inhibitor targeting programmed death ligand 1 (PD-L1) with anti-tumor activity for the study of solid tumors.Purity:98.8% (SDS-PAGE); 96.3% (SEC-HPLC) - 98.8% (SDS-PAGE); 96.3% (SEC-HPLC)Color and Shape:LiquidMolecular weight:153.3 kDaTubulin-IN-53
Tubulin-IN-53 is a potent inhibitor of microtubulin (Tubulin) with an IC50 of 6.06 μM. By targeting the colchicine binding site on tubulin, Tubulin-IN-53 hinders tubulin polymerization, disrupting the microtubule network. It induces cell cycle arrest at the G2/M phase and apoptosis (apoptosis) in MCF-7 cells, while inhibiting cell migration. This compound also leads to a reduction in mitochondrial membrane potential and an increase in reactive oxygen species (ROS) accumulation. Additionally, Tubulin-IN-53 disrupts angiogenesis in human umbilical vein endothelial cells and is applicable in research on cancers such as breast and lung cancer.Color and Shape:Odour SolidTizanidine
CAS:Tizanidine, an α2-adrenergic receptor agonist, suppresses the release of neurotransmitters from central nervous system (CNS) noradrenergic neurons.Formula:C9H8ClN5SPurity:99.11%Color and Shape:White SolidMolecular weight:253.71NEP162
CAS:NEP162 is a BRD4 PROTAC degrader with DC50 values of 1.2 μM in SW480 cells and 1.6 μM in U2OS cells. NEP162 exhibits antiproliferative activity, effectively inhibiting tumor growth and inducing apoptosis. It is applicable in research on cancers such as osteosarcoma, colorectal cancer, and non-small cell lung cancer.Formula:C50H56ClN11O3SColor and Shape:SolidMolecular weight:926.57ACP-0052
CAS:ACP-0052(SL-052, ACP-SL-052) is a photosensitizer based on hypoclintin that may be used in the treatment of prostate cancer.Formula:C35H32N2O7Color and Shape:SolidMolecular weight:592.648PROTAC BRD4 Degrader-33
PROTACBRD4 Degrader-33 is an enzyme-activated, click-responsive BRD4 PROTAC degrader designed with effective tumor microenvironment responsiveness. This compound exhibits exceptional penetration into tumor tissues and effectively inhibits PD-L1 protein expression. In the 4T1 tumor mouse model, PROTACBRD4 Degrader-33 demonstrates potent antitumor immunomodulatory activity.Color and Shape:Odour SolidMB-314
MB-314 is a humanized IgG1 monoclonal antibody (mAb) targeting Lewis Y. This compound enhances antibody-dependent cell-mediated cytotoxicity (ADCC) activity and increases the release of IFN-γ, TNF-α, MCP-1, and IL-6. MB-314 is applicable in cancer research.Color and Shape:Odour LiquidVCP/p97 IN-3
VCP/p97 IN-3 is an allosteric inhibitor of VCP/p97. It exhibits inhibitory activity against VCP, with an IC50 of 9 nM, and shows IC50 values of 12 nM (N660K) and 19 nM (V474A/D649A) for mutant VCP proteins. VCP/p97 IN-3 increases the levels of K48 ubiquitination and caspase-3. It activates endoplasmic reticulum stress and the unfolded protein response (UPR). In a subcutaneous xenograft mouse model with RPMI-8226 cells, VCP/p97 IN-3 suppresses tumor growth. This compound is applicable for research in multiple myeloma.Color and Shape:Odour SolidPI3Kα-IN-14
PI3Kα-IN-14 (compound F8), a potent PI3Kα inhibitor, exhibits an IC50 value of 0.14 nM and markedly diminishes mitochondrial membrane potential, resulting inPurity:98%Color and Shape:Odour SolidHalleridone
CAS:Halleridone, a natural product, is identified in Teuanchum decipiens and Abeliophyllum distichum.Formula:C8H10O3Color and Shape:SolidMolecular weight:154.165PROTAC c-Met degrader-5
PROTACc-Met degrader-5 (Compound D19) is an orally active c-Met PROTAC degrader, with a DC50 of 0.42 nM in EBC-1 cells and 0.32 nM in Hs746T cells. It effectively induces apoptosis, causes G1 cell cycle arrest, and inhibits cell migration and invasion. This compound shows strong antiproliferative and degradative effects on c-Met-dependent cancer cells and those resistant to Tepotinib.Color and Shape:Odour SolidZeluvalimab
CAS:Zeluvalimab (AMG-404) is a monoclonal antibody designed to target the PD-1 receptor, and is utilized in cancer research [1].Color and Shape:LiquidThalidomide-5-propargyne-NH2 hydrochloride
CAS:Thalidomide derivative for CRBN protein recruitment, used in PROTACs production for protein degradation.Formula:C16H14ClN3O4Color and Shape:SolidMolecular weight:347.753Thalidomide-O-C4-COOH
CAS:Thalidomide-O-C4-COOH is a synthetic E3 ligase linker derived from Thalidomide for PROTAC tech.Formula:C18H18N2O7Color and Shape:SolidMolecular weight:374.3447Bromoiodoacetamide
CAS:Bromoiodoacetamide (I-HAcAm): cytotoxic, induces ROS & apoptosis in HepG-2 cells.Formula:C2H3BrINOColor and Shape:SolidMolecular weight:263.86KP1019
CAS:KP1019 is now discontinued.Formula:C21H19Cl4N6RuColor and Shape:SolidMolecular weight:598.30PD-1/PD-L1-IN-51
PD-1/PD-L1-IN-51 (Compound III-4) is an inhibitor of PD-1/PD-L1 (IC50: hPD-L1 at 2.9 nM). It binds directly to PD-L1, blocking the interaction between PD-1 and PD-L1, and enhancing the release of IFN-γ. Additionally, PD-1/PD-L1-IN-51 exhibits antitumor activity.Color and Shape:Odour SolidPD-1/PD-L1-IN-52
PD-1/PD-L1-IN-52 (Compound Ⅲ-5) is an orally active inhibitor of PD-1/PD-L1 interaction, exhibiting an IC50 of 109.9 nM. It demonstrates antitumor activity in a C57BL/6 mouse model of MC38 colon carcinoma cells expressing human PD-1, achieving a tumor growth inhibition (TGI) rate of 49.6%.Color and Shape:Odour SolideIF4A3-IN-7
CAS:eIF4A3-IN-7: Potent eIF4A3 inhibitor, potential cancer/dysproliferation research (WO2019161345A1, Compound 8).Formula:C26H25NO7Color and Shape:SolidMolecular weight:463.486Human PD-L1 inhibitor V
CAS:Human PD-L1 Inhibitor V is a peptide that binds to the human PD-1 protein with an affinity characterized by a dissociation constant (Kd) of 3.32 μM, effectivelyFormula:C65H104N20O18SPurity:98%Color and Shape:SolidMolecular weight:1485.71Mas7
CAS:Amphiphilic peptide Mas7, a structural analogue of mastoparan is a known activator of heterotrimeric Gi-proteins and its downstream effectors.Formula:C67H124N18O15Purity:98%Color and Shape:SolidMolecular weight:1421.81Ac-AAVALLPAVLLALLAP-LEVD-CHO
CAS:Ac-AAVALLPAVLLALLAP-LEVD-CHO is a cell-permeable inhibitor of caspase-4 that exhibits antitumor activity [1].Formula:C96H164N20O25Purity:98%Color and Shape:SolidMolecular weight:1998.45NLRP3-IN-55
NLRP3-IN-55 (Compound 19) is an effective inhibitor of NLRP3, exhibiting an inhibitory concentration (IC50) of 0.34 μM. It targets the NLRP3 protein directly with a dissociation constant (KD) of 0.45 μM, effectively blocking the assembly and activation of the NLRP3 inflammasome. This action results in anti-inflammatory effects and inhibits cell pyroptosis.Formula:C32H30ClFN2O4Color and Shape:SolidMolecular weight:561.04CALP1
CAS:Cell-permeable CaM agonist; activates phosphodiesterase, binds to Ca2+ channels, inhibits cytotoxicity (IC50=52μM), protects cells, reduces inflammation.Formula:C40H75N9O10Purity:98%Color and Shape:SolidMolecular weight:842.09RIPK1-IN-27
RIPK1-IN-27 (compound 19) is an inhibitor of RIPK1.Formula:C27H28N4O3Color and Shape:SolidMolecular weight:456.54SSE1806
SSE1806, a podophyllotoxin derivative (a natural antimitotic agent), functions as a microtubule/tubulin inhibitor, exhibiting potent anticancer andFormula:C21H18N2O5Color and Shape:SolidMolecular weight:378.38LTB
LTB is a prodrug formed through the conjugation of the glycolysis inhibitor (Lonidamine) and the PD1/PDL1 blocker (BMS-1) via a thioketal bond. LTB can encapsulate the photosensitizer Chlorin e6 (Ce6), constructing a co-delivery photodynamic nanoplatfform through self-assembly (LTB-6 NPs).Formula:C53H59Cl2N3O7S2Color and Shape:SolidMolecular weight:985.09tetrathiomolybdate
CAS:Tetrathiomolybdate (TM) promotes the dimerization of the metal-binding domain (WLN4) of the cellular copper efflux protein ATP7B through its characteristicFormula:MoS4Color and Shape:SolidMolecular weight:224.22-Methylbiphenyl-oxadiazole-NH-Ph-NH-PEG3-C2-NH-Boc
2-Methylbiphenyl-oxadiazole-NH-Ph-NH-PEG3-C2-NH-Boc is the PD-L1 ligand-linker polymer of AUTACPD-L1degrader-3. It can be utilized in the synthesis of AUTAC.Formula:C35H45N5O6Color and Shape:SolidMolecular weight:631.76LP23
LP23, a non-arylmethylamine PD-1/PD-L1 inhibitor (IC 50: 16.7 nM), exhibits anti-tumor activity through the restoration of immune cell function in HepG2/JurkatFormula:C27H27N3O5SPurity:98%Color and Shape:SolidMolecular weight:505.59LSD1-IN-27
CAS:LSD1-IN-27 inhibits LSD1 (IC50=13 nM), blocks gastric cancer cell stemness/migration, reduces PD-L1, and boosts T-cell response.Formula:C24H25N3Purity:99.98%Color and Shape:SoildMolecular weight:355.48GGTI298 Trifluoroacetate
CAS:GGTI298 trifluoroacetate (GGTI298TFA salt) is a geranylgeranyltransferase I inhibitor that causes cell cycle arrest and induces apoptosis.Formula:C27H33N3O3S·C2HF3O2Purity:98.07% - >99.99%Color and Shape:SolidMolecular weight:593.66Cytostatin
CAS:Cytostatin: Natural antitumor, inhibits cell adhesion, blocks B16 melanoma, induces apoptosis, selectively targets PP2A (IC50 = 29 nM).Formula:C21H33O7PColor and Shape:SolidMolecular weight:428.462CDK-TCIP1
CAS:CDK-TCIP1 is a bivalent molecule that links the CDK9 inhibitor SNS-032 with the BCL6 ligand BI3812. It effectively and specifically kills cells overexpressing BCL6, with an EC50 of 7.7 nM for SUDHL5 cells.Formula:C48H62ClN11O8S2Color and Shape:SolidMolecular weight:1020.66DH-18
DH-18 is an inhibitor of matrix metalloproteinase-2 (MMP-2), exhibiting IC50 values of 139.45 nM for MMP-2, 518.11 nM for MMP-9, and 833.34 nM for MMP-8. The compound promotes cell apoptosis and causes cell cycle arrest in the G0/G1 phase. DH-18 also inhibits cell growth, making it potential for research in chronic myeloid leukemia.Formula:C26H23F6N3O5SColor and Shape:SolidMolecular weight:603.53PROTAC EZH2 Degrader-3
PROTAC EZH2 Degrader-3 (compound ZJ-20) is a potent EZH2 degrader that exhibits strong inhibitory effects not only on EZH2 protein expression but also on the levels of other PRC2 subunits and H3k27me3 protein. Additionally, PROTAC EZH2 Degrader-3 demonstrates antiproliferative activity by blocking the cell cycle at the G0-G1 phase and inducing apoptosis (cell death). At a concentration of 5 μM and over a period of 24 hours, it effectively suppresses the expression of these critical proteins involved in cell regulation and growth.Formula:C56H68N8O8Color and Shape:SolidMolecular weight:981.19Bfl-1-IN-5
Bfl-1-IN-5 (Compound (R,R,S)-26) is a selective inhibitor of Bfl-1, demonstrating an IC50 of 0.022 μM. This compound enhances the activity of caspase-3/7, with an EC50 of 0.37 μM, and also inhibits the viability of SU-DHL-1 cells, showing an EC50 of 1.3 μM.Formula:C24H24F3N3O2Color and Shape:SolidMolecular weight:443.46LBM22
LBM22, a CLK2 inhibitor, exhibits an IC50 value of 3.9 nM. It possesses anti-proliferative properties by inhibiting the phosphorylation of SR proteins. Additionally, LBM22 downregulates the expression of Wnt-related proteins and anti-apoptotic proteins, making it applicable in the study of non-small cell lung cancer.Formula:C28H22F2N6O2Color and Shape:SolidMolecular weight:512.51PIM-1/CK2-IN-2
PIM-1/CK2-IN-2 (compound 3aA) is an inhibitor of the PIM-1/CK2 enzymes. This compound can induce the mitochondrial apoptosis pathway in CCRF-CEM cells and is utilized in cancer research.Formula:C15H8Br4N2OColor and Shape:SolidMolecular weight:551.85BCL-XL-IN-1
BCL-XL-IN-1 (Compound 11) is a selective inhibitor of BCL-XL, exhibiting a Ki of less than 0.01 nM against BCL-XLTR-FERT. It is primarily used in cancer research.Formula:C46H55N7O6SColor and Shape:SolidMolecular weight:834.04LSD1-IN-36
LSD1-IN-36, an effective LSD1 inhibitor with an IC50 value of 0.8 nM, induces cell apoptosis and arrests the cell cycle. This compound also exhibits antitumor activity.Formula:C22H25N3O6SColor and Shape:SolidMolecular weight:459.52Terrein
CAS:Terrain (NSC 291308), a fungal metabolite, reduces age-related inflammation via Nrf2/ERK1/2/HO-1 and inhibits IL-6 in human fibroblasts.Formula:C8H10O3Color and Shape:SolidMolecular weight:154.16Antiproliferative agent-59
Antiproliferative agent-59 (Compound 14u) acts as an inhibitor of tubulin polymerization. Demonstrating anticancer activity in Huh7, SGC-7901, and MCF-7 cell lines, this compound achieves IC50 values of 0.03, 0.18, and 0.13 μM, respectively. Additionally, it arrests the cell cycle at the G2/M phase and induces apoptosis in Huh7 cells. In a xenograft mouse model utilizing Huh7 cells, Antiproliferative agent-59 exhibits antitumor effects against hepatocellular carcinoma without significant toxicity.Formula:C26H22N2O3Color and Shape:SolidMolecular weight:410.46Mcl-1 inhibitor 15
Mcl-1 Inhibitor 15 (Compound (Ra)-15), with a K i of 0.02 nM, is utilized in cancer research [1].Formula:C40H42ClFN6O4SColor and Shape:SolidMolecular weight:757.32CDD-2807
CDD-2807 is a serine/threonine kinase 33 (STK33) inhibitor with an IC50 of 9.2 nM. In mice, CDD-2807 demonstrates no significant toxicity and can cross the blood-testis barrier without accumulating in the brain. It offers reversible contraceptive effects, indicating potential for development as a male contraceptive.Formula:C29H26N4OMolecular weight:446.21066MD-265
CAS:MD-265 is a PROTAC degrader that targets and degrades MDM2, leading to the activation of p53 in cancer cells with wild-type p53. MD-265 achieves complete tumor regression and enhances long-term survival in leukemic mice.Formula:C50H51Cl2FN6O6Molecular weight:921.88Subtilisin
CAS:Marstacimab (PF-06741086) is a neutralizing antibody that binds and inhibits human tissue factor pathway inhibitors.Color and Shape:SolidPROTAC NCOA4 degrader-1
PROTACNCOA4 degrader-1 (Compound V3) is a PROTAC-based degrader of NCOA4, exhibiting a DC50 of 3 nM in HeLa cells. Besides acting as a ferroptosis inhibitor, this compound effectively reduces the levels of NCOA4 and decreases intracellular ferrous (Fe2+) levels. Moreover, PROTACNCOA4 degrader-1 ameliorates liver damage in a CCl4-induced acute liver injury model.Color and Shape:Odour Solid
